Clinical trials: Nr-axSpa
Axial Spondyloarthritis, Ankylosing Spondylitis
Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy
The goal of this clinical trial is to find out if the study drug will work as a new therapy for axSpA patients. This study is placebo-controlled, and evaluates if study drug can treat symptoms of axSpA, including global disease…
- Conditions
- Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpA, Nr-axSpA
- Trial name
- V-SPINE (NCT06526377)
- Testing
- vilamakitug
- Volunteers
- 150 people
- Sponsor
- XBiotech, Inc.
Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis
Efficacy and Safety Study of SUNPG1622
This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.
- Trial name
- NCT02980705
- Testing
- SUNPG1622 I dose
- Where
- 4 sites in United States, Hungary and 2 more
- Volunteers
- 180 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Axial Spondyloarthritis
Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis
The objective of this multicenter, randomized, double-blind study was to evaluate the efficacy and safety of continuing versus withdrawing therapy with adalimumab 40 mg given every other week SC in maintaining remission in…
- Trial name
- NCT01808118
- Testing
- adalimumab
- Volunteers
- 673 people
- Sponsor
- AbbVie
Axial Spondyloarthritis, Ankylosing Spondylitis
A Study to Assess the Safety of Subcutaneous Secukinumab for Treatment in Adult Indian Participants With Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS), and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
The aim of this study is to assess the safety of secukinumab in Indian adult participants with axSpA, AS, and nr-axSpA over a 16-week treatment period.
- Conditions
- Axial Spondyloarthritis, Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis
- Trial name
- NCT07737730
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Axial Spondyloarthritis, Non-Radiographic
A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
This study will evaluate the efficacy and safety of 608 in patients with nr-axSpA.
- Trial name
- NCT07349329
- Testing
- 608
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Ankylosing Spondylitis
Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA
The purpose of this global study was to demonstrate the efficacy, safety, and tolerability of an intravenous (i.v.) regimen of secukinumab compared to placebo in participants with active ankylosing spondylitis (AS) or…
- Trial name
- NCT04156620
- Testing
- Secukinumab
- Where
- 102 sites in United States, Belgium and 16 more
- Volunteers
- 527 people
- Sponsor
- Novartis Pharmaceuticals
Spondyloarthritis
SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis
The purpose of the study was to evaluate the efficacy and safety of secukinumab 150 mg compared to placebo in the early management (Baseline to Week 8) of spinal pain, disease activity, fatigue, and predictability of disease…
- Trial name
- SKIPPAIN (NCT03136861)
- Testing
- AIN457
- Where
- 66 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 383 people
- Sponsor
- Novartis Pharmaceuticals
Axial Spondyloarthritis, Ankylosing Spondylitis
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing…
- Conditions
- Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
- Trial name
- BE MOVING (NCT04436640)
- Testing
- Bimekizumab
- Where
- 75 sites in United States, Belgium and 12 more
- Volunteers
- 508 people
- Sponsor
- UCB Biopharma SRL
Non-radiographic Spondyloarthritis
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
The purpose of this study was to demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with nr-axSpA at Week 16 as well as Week 52 and long term efficacy and safety up to Week…
- Trial name
- PREVENT (NCT02696031)
- Testing
- Secukinumab
- Where
- 139 sites in United States, Australia and 22 more
- Volunteers
- 555 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis, Psoriatic Arthritis
Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis
The primary objective of this study is to evaluate the effect of filgotinib on semen parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-Radiographical Axial Spondyloarthritis
- Trial name
- MANTA-RAy (NCT03926195)
- Testing
- Filgotinib, Standard of Care
- Where
- 71 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 109 people
- Sponsor
- Lakefront Biotherapeutics NV
Active Non-radiographic Axial Spondyloarthritis
A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis
The study is being conducted to evaluate the efficacy and safety of SHR-1314 injection in adult patients with active non-radiographic axial spondyloarthritis.
- Trial name
- NCT06860750
- Testing
- SHR-1314 Injection
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Axial Spondyloarthritis
AScalate: Treat-to-target in Axial Spondyloarthritis
This was a randomized, parallel-group, open-label, multicenter study in patients with active axSpA. The aim of the study was to demonstrate that the efficacy of a T2T approach (with secukinumab as a first-line biologic) was…
- Trial name
- AScalate (NCT03906136)
- Testing
- Secukinumab/Adalimumab-Biosimilar, Standard-of-care
- Where
- 47 sites in France, Germany
- Volunteers
- 304 people
- Sponsor
- Novartis Pharmaceuticals
Non-radiographic Axial Spondyloarthritis
A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial Spondyloarthritis
This study is to evaluate the efficacy and safety of SHR0302 in subjects with active non-radiographic axial spondyloarthritis.
- Trial name
- NCT05324631
- Testing
- SHR0302
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis and with signs of inflammation will be randomly assigned to receive certolizumab pegol (CZP) 200 mg every two weeks or placebo.
- Conditions
- Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
- Trial name
- C-AXSPAND (NCT02552212)
- Testing
- Certolizumab Pegol
- Where
- 105 sites in United States, Australia and 7 more
- Volunteers
- 317 people
- Sponsor
- UCB BIOSCIENCES GmbH
Spondyloarthritis
Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)
The purpose of this study is to evaluate the effect of treatment withdrawal compared to continued treatment with golimumab (GLM) administered by subcutaneous (SC) injection on the incidence of a "flare" in non-radiographic axial…
- Trial name
- NCT03253796
- Testing
- Golimumab
- Where
- 71 sites in Czechia, Germany and 7 more
- Volunteers
- 323 people
- Sponsor
- Merck Sharp & Dohme LLC
Axial Spondyloarthritis
A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
This study will evaluate the effect and safety of 608 in patients with nr-axSpA.
- Trial name
- NCT06222671
- Testing
- 608
- Where
- 6 sites in China
- Volunteers
- 180 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Crohn's Disease, Ulcerative Colitis (UC)
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.
- Conditions
- Crohn's Disease, Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), Psoriatic Arthritis
- Trial name
- IMPROVE (NCT03223012)
- Where
- 15 sites in Portugal
- Volunteers
- 116 people
- Sponsor
- AbbVie
Rheumatoid Arthritis, Ankylosing Spondylarthritis
Yuflyma® (Adalimumab), Patient Experience After Switching
Patient preference and experience can impact patients' adherence and persistence regarding a treatment, especially when switching.
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylarthritis, Axial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- YU-MATTER (NCT05427942)
- Testing
- Adalimumab
- Where
- 2 sites in France
- Volunteers
- 300 people
- Sponsor
- Celltrion HealthCare France
Spondylitis, Ankylosing
Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA
The purpose of this study is to study the benefits and risks of etanercept withdrawal in patients who have achieved a significant clinical response.
- Trial name
- RE-EMBARK (NCT02509026)
- Testing
- Etanercept
- Where
- 82 sites in United States, Australia and 12 more
- Volunteers
- 210 people
- Sponsor
- Pfizer
Autoimmune Diseases, Ulcerative Colitis
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
The most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation.
- Conditions
- Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma
- Trial name
- NCT06587828
- Testing
- Companion blood samples with procedure
- Where
- 11 sites in United States
- Volunteers
- 238 people
- Sponsor
- TScan Therapeutics, Inc.